QQQ   380.00 (+0.23%)
AAPL   148.85 (-0.31%)
MSFT   323.17 (+4.21%)
FB   312.22 (-1.14%)
GOOGL   2,924.35 (+4.96%)
TSLA   1,037.86 (+1.91%)
AMZN   3,392.49 (+0.49%)
NVDA   244.51 (-1.08%)
BABA   169.23 (-0.45%)
NIO   39.31 (-2.87%)
CGC   12.78 (-2.96%)
GE   103.85 (-3.34%)
AMD   122.28 (-0.53%)
MU   68.24 (-1.02%)
T   25.06 (-1.22%)
F   15.51 (-2.70%)
ACB   6.84 (-2.70%)
DIS   169.55 (-1.45%)
PFE   42.97 (-1.35%)
BA   206.61 (-1.53%)
AMC   34.76 (-3.58%)
QQQ   380.00 (+0.23%)
AAPL   148.85 (-0.31%)
MSFT   323.17 (+4.21%)
FB   312.22 (-1.14%)
GOOGL   2,924.35 (+4.96%)
TSLA   1,037.86 (+1.91%)
AMZN   3,392.49 (+0.49%)
NVDA   244.51 (-1.08%)
BABA   169.23 (-0.45%)
NIO   39.31 (-2.87%)
CGC   12.78 (-2.96%)
GE   103.85 (-3.34%)
AMD   122.28 (-0.53%)
MU   68.24 (-1.02%)
T   25.06 (-1.22%)
F   15.51 (-2.70%)
ACB   6.84 (-2.70%)
DIS   169.55 (-1.45%)
PFE   42.97 (-1.35%)
BA   206.61 (-1.53%)
AMC   34.76 (-3.58%)
QQQ   380.00 (+0.23%)
AAPL   148.85 (-0.31%)
MSFT   323.17 (+4.21%)
FB   312.22 (-1.14%)
GOOGL   2,924.35 (+4.96%)
TSLA   1,037.86 (+1.91%)
AMZN   3,392.49 (+0.49%)
NVDA   244.51 (-1.08%)
BABA   169.23 (-0.45%)
NIO   39.31 (-2.87%)
CGC   12.78 (-2.96%)
GE   103.85 (-3.34%)
AMD   122.28 (-0.53%)
MU   68.24 (-1.02%)
T   25.06 (-1.22%)
F   15.51 (-2.70%)
ACB   6.84 (-2.70%)
DIS   169.55 (-1.45%)
PFE   42.97 (-1.35%)
BA   206.61 (-1.53%)
AMC   34.76 (-3.58%)
QQQ   380.00 (+0.23%)
AAPL   148.85 (-0.31%)
MSFT   323.17 (+4.21%)
FB   312.22 (-1.14%)
GOOGL   2,924.35 (+4.96%)
TSLA   1,037.86 (+1.91%)
AMZN   3,392.49 (+0.49%)
NVDA   244.51 (-1.08%)
BABA   169.23 (-0.45%)
NIO   39.31 (-2.87%)
CGC   12.78 (-2.96%)
GE   103.85 (-3.34%)
AMD   122.28 (-0.53%)
MU   68.24 (-1.02%)
T   25.06 (-1.22%)
F   15.51 (-2.70%)
ACB   6.84 (-2.70%)
DIS   169.55 (-1.45%)
PFE   42.97 (-1.35%)
BA   206.61 (-1.53%)
AMC   34.76 (-3.58%)
NYSE:AMRX

Amneal Pharmaceuticals Earnings Date, Estimates, & History

$5.34
-0.20 (-3.61 %)
(As of 10/27/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.27
$5.50
50-Day Range
$4.77
$5.85
52-Week Range
$3.90
$7.45
Volume
699,086 shs
Average Volume
1.29 million shs
Market Capitalization
$1.61 billion
P/E Ratio
89.00
Dividend Yield
N/A
Beta
1.22

Earnings Summary

Upcoming
Earnings Date
Nov. 5
Estimated

Actual EPS
(Aug. 8)
$0.25
Beat By $0.07

Consensus EPS
(Aug. 8)
$0.18

Last Year's Q3 EPS
(8/6/2020)
$0.13

Skip Charts & View Estimated and Actual Earnings Data

Amneal Pharmaceuticals Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Amneal Pharmaceuticals Estimated Revenue and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Amneal Pharmaceuticals (NYSE:AMRX) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20212$0.10$0.16$0.13 
Q2 20212$0.14$0.19$0.17 
Q3 20212$0.18$0.19$0.19 
Q4 20212$0.20$0.21$0.21 
FY 20218$0.62$0.75$0.69

AMRX Earnings Information

Amneal Pharmaceuticals last posted its earnings data on August 8th, 2021. The reported $0.25 EPS for the quarter, topping analysts' consensus estimates of $0.18 by $0.07. The company had revenue of $535.10 million for the quarter, compared to the consensus estimate of $523.26 million. Its revenue was up 15.1% on a year-over-year basis. Amneal Pharmaceuticals has generated $0.52 earnings per share over the last year ($0.06 diluted earnings per share) and currently has a price-to-earnings ratio of 89.0. Earnings for Amneal Pharmaceuticals are expected to grow by 7.32% in the coming year, from $0.82 to $0.88 per share. Amneal Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Friday, November 5th, 2021 based off prior year's report dates.

Amneal Pharmaceuticals (NYSE:AMRX) Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueActions
11/5/2021
(Estimated)
        
8/8/20216/30/2021$0.18$0.25+$0.07$0.36$523.26 million$535.10 million    
5/6/20213/31/2021$0.18$0.20+$0.02$0.34$514.73 million$493.10 million  
2/25/202112/31/2020$0.13$0.14+$0.01$0.24$506.91 million$510.00 million  
11/6/20209/30/2020$0.12$0.16+$0.04$0.32$482.22 million$519.30 million  
8/6/20206/30/2020$0.10$0.13+$0.03$0.28$454.26 million$464.60 million  
5/11/20203/31/2020$0.09$0.20+$0.11($0.42)$446.12 million$498.50 million  
2/26/2020Q4 2019$0.05$0.08+$0.03$0.37$382.10 million$397.00 million  
11/6/20199/30/2019$0.13$0.04($0.09)$2.03$403.90 million$378.30 million  
8/5/2019Q2 2019$0.14$0.09($0.05)$0.25$420.12 million$404.60 million  
5/9/2019Q1$0.18$0.11($0.07)$0.59$438.18 million$446.00 million  
2/28/2019Q4 2018$0.26$0.32+$0.06$0.71$478.06 million$497.53 million  
11/7/2018Q3$0.27$0.28+$0.01$0.47$486.01 million$476.50 million  
8/9/2018Q2 2018$0.23$0.24+$0.01$0.63$460.82 million$462.33 million
3/1/2018Q4 2017$0.12$0.11($0.01)$4.40$196.26 million$182.91 million
11/9/2017Q3 2017$0.19$0.23+$0.04$1.15$203.66 million$206.39 million
8/9/2017Q2 2017$0.14$0.18+$0.04$0.64$196.14 million$202.08 million
5/10/2017Q1 2017$0.12$0.11($0.01)$1.59$190.70 million$184.40 million
3/1/2017Q4 2016$0.16$0.16$4.23$219.86 million$198.42 million
11/9/2016Q3 2016$0.40$0.37($0.03)$3.25$235.06 million$227.91 million
8/9/2016Q2 2016$0.33$0.21($0.12)$0.46$233.63 million$172.59 million
5/10/2016Q1 2016$0.43$0.43$1.01$255.95 million$225.51 million
2/22/2016Q4 2015$0.44$0.62+$0.18$1.08$225.80 million$282.09 million
11/9/2015Q3 2015$0.39$0.40+$0.01$0.31$212.50 million$221.10 million
8/10/2015Q2 2015$0.35$0.34($0.01)$0.71$199.53 million$214.18 million
5/11/2015Q1 2015$0.20$0.09($0.11)$0.27$143.78 million$143.10 million
2/24/2015Q4 2014$0.11$0.16+$0.05$0.32$124.76 million$131.21 million
11/4/2014Q3 2014$0.40$0.33($0.07)$0.44$152.36 million$158.00 million
8/6/2014Q2 2014$0.39$0.60+$0.21$0.70$155.85 million$188.12 million
5/1/2014Q1 2014$0.13$0.24+$0.11$0.39$118.73 million$118.72 million
2/20/2014Q4 2013$0.07($0.02)($0.09)$0.10$122.32 million$100.74 million
11/4/2013Q3 2013($0.06)$0.25+$0.31$0.50$109.18 million$132.64 million
8/8/2013Q2 2013$0.04$0.23+$0.19$0.38$118.05 million$129.63 million
5/1/2013Q1 2013$0.23$0.37+$0.14($0.81)$134.39 million$148.49 million
(Earnings results data provided by Zacks Investment Research)












Amneal Pharmaceuticals (NYSE:AMRX) Earnings Frequently Asked Questions

When is Amneal Pharmaceuticals's earnings date?

Amneal Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Friday, November 5th, 2021 based off last year's report dates. Learn more on AMRX's earnings history

Did Amneal Pharmaceuticals beat their earnings estimates last quarter?

In the previous quarter, Amneal Pharmaceuticals (NYSE:AMRX) reported $0.25 earnings per share (EPS) to beat the analysts' consensus estimate of $0.18 by $0.07. Learn more on AMRX's earnings details

How can I listen to Amneal Pharmaceuticals's earnings conference call?

The conference call for Amneal Pharmaceuticals's latest earnings report can be listened to online. Listen to Conference Call

How can I read Amneal Pharmaceuticals's conference call transcript?

The conference call transcript for Amneal Pharmaceuticals's latest earnings report can be read online. Read Transcript

How much revenue does Amneal Pharmaceuticals generate each year?

Amneal Pharmaceuticals (NYSE:AMRX) has a recorded annual revenue of $1.99 billion.

How much profit does Amneal Pharmaceuticals generate each year?

Amneal Pharmaceuticals (NYSE:AMRX) has a recorded net income of $91.06 million. AMRX has generated $0.52 earnings per share over the last four quarters.

What is Amneal Pharmaceuticals's price-to-earnings ratio?

Amneal Pharmaceuticals (NYSE:AMRX) has a trailing price-to-earnings ratio of 89.00 and a forward price-to-earnings ratio of 6.51. The price/earnings-to-growth ratio is 0.25.

What is Amneal Pharmaceuticals's EPS forecast for next year?

Amneal Pharmaceuticals's earnings are expected to grow from $0.82 per share to $0.88 per share in the next year, which is a 7.32% increase.

This page was last updated on 10/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.